LYEL - Lyell Immunopharma Inc

25.5
3.040   11.922%

Share volume: 231,146
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.20%

PREVIOUS CLOSE
CHG
CHG%
$22.46
3.04
0.14%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 22%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
15.65%
1 Month
7.55%
3 Months
-18.48%
6 Months
95.10%
1 Year
3,642.84%
2 Year
994.42%
Key data
Stock price
$25.50
P/E Ratio 
0.00
DAY RANGE
$22.14 - $26.65
EPS 
-$3.20
52 WEEK RANGE
$0.39 - $45.00
52 WEEK CHANGE
$3,730.55
MARKET CAP 
311.990 M
YIELD 
N/A
SHARES OUTSTANDING 
21.218 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-05-2025
BETA 
1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$101,560
AVERAGE 30 VOLUME 
$113,976
Company detail
CEO: Elizabeth Homans
Region: US
Website: lyell.com
Employees: 270
IPO year: 2021
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.

Recent news